Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 10 years, with Q3 2025 value amounting to $1.5 million.

  • Viridian Therapeutics, Inc.\DE's Change in Account Payables fell 4723.55% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 7219.37%. This contributed to the annual value of -$73000.0 for FY2024, which is 9939.37% up from last year.
  • Viridian Therapeutics, Inc.\DE's Change in Account Payables amounted to $1.5 million in Q3 2025, which was down 4723.55% from $4.6 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Change in Account Payables high stood at $8.0 million for Q3 2022, and its period low was -$6.6 million during Q1 2023.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Change in Account Payables averaged around $474105.3, with its median value being $482000.0 (2024).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Change in Account Payables crashed by 2154193.55% in 2023, and later soared by 281296.3% in 2024.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Change in Account Payables stood at -$1.4 million in 2021, then surged by 224.11% to $1.7 million in 2022, then crashed by 186.88% to -$1.5 million in 2023, then tumbled by 158.77% to -$3.9 million in 2024, then soared by 139.41% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $4.6 million for Q2 2025, and $1.8 million during Q1 2025.